Literature DB >> 25806333

Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?

Howard West1.   

Abstract

Entities:  

Year:  2014        PMID： 25806333      PMCID： PMC4367667          DOI： 10.3978/j.issn.2218-6751.2014.09.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  2 in total

1.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

2.  Programmed death ligand-1 expression in non-small cell lung cancer.

Authors:  Vamsidhar Velcheti; Kurt A Schalper; Daniel E Carvajal; Valsamo K Anagnostou; Konstantinos N Syrigos; Mario Sznol; Roy S Herbst; Scott N Gettinger; Lieping Chen; David L Rimm
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662
  2 in total
  7 in total

1.  Cancer Immunotherapy, Part 3: Challenges and Future Trends.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-08

Review 2.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.

Authors:  Shuhang Wang; Yongping Song; Feifei Yan; Delong Liu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

3.  Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

Authors:  F Grossi; E Rijavec; C Genova; G Barletta; F Biello; C Maggioni; G Burrafato; C Sini; M G Dal Bello; K Meyer; J Roder; H Roder; J Grigorieva
Journal:  Br J Cancer       Date:  2016-11-29       Impact factor: 7.640

Review 4.  Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.

Authors:  Yvonne Le Ang; Joline Sj Lim; Ross A Soo
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147

Review 5.  EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.

Authors:  Shuhang Wang; Stella T Tsui; Christina Liu; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-07-22       Impact factor: 17.388

6.  High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.

Authors:  Xiaofang Guo; Juan Wang; Jietian Jin; Hao Chen; Zijun Zhen; Wenqi Jiang; Tongyu Lin; Huiqiang Huang; Zhongjun Xia; Xiaofei Sun
Journal:  Transl Oncol       Date:  2018-04-24       Impact factor: 4.243

7.  Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.

Authors:  Young Kwang Chae; Won Bin Kim; Andrew A Davis; Lee Chun Park; Jonathan F Anker; Nicholas I Simon; Kyunghoon Rhee; Junho Song; Anderson Cho; Sangmin Chang; Taeyeong Ko; Michael Oh; Manali Bhave; Pedro Viveiros
Journal:  Transl Lung Cancer Res       Date:  2020-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.